Marksans Pharma will host its earnings conference call for the first quarter of fiscal year 2027 on Thursday, August 13, 2026, at 4:30 PM IST. The management team will present and discuss the company’s unaudited financial results for the quarter ended June 30, 2026, covering both standalone and consolidated performance metrics.

The disclosure is made pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company informed BSE Limited and the National Stock Exchange of India Limited regarding the schedule on August 03, 2026.

Conference Call Details

Founder, Chairman and Managing Director Mark Saldanha and Chief Financial Officer Jitendra Sharma are scheduled to lead the discussion. DAM Capital Advisors Ltd will manage the proceedings, with Nitin Agarwal serving as the analyst lead.

Participants can access the call via universal dial-in numbers +91 22 6280 1384 or +91 22 7115 8285. International participants may use the toll-free numbers provided for Hong Kong, Singapore, the UK, and the USA.

Investors are advised to dial in five to ten minutes prior to the scheduled start time to ensure connectivity. For further assistance, DAM Capital Advisors Limited can be contacted at +91 22 4202 2568 / 2638.

Post-Call Resources

Following the conference call, Marksans Pharma will host the presentation, audio recording, and transcript on its official website. These materials will be available at https://www.marksanspharma.com/earnings-call-transcripts.html for public access.

Marksans Pharma Limited has published a newspaper advertisement in Business Standard and Lakshadeep on July 30, 2026, announcing the schedule for its 34th Annual General Meeting (AGM). The meeting is set for Thursday, August 27, 2026, at 11:00 a.m. and will be conducted exclusively through Video Conferencing (VC) or Other Audio Visual Means (OAVM), in compliance with Ministry of Corporate Affairs (MCA) circulars. This disclosure ensures shareholders are aware of the procedural timeline and access mechanisms for the upcoming governance event.

The filing was made pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Harshavardhan Panigrahi, Company Secretary, signed the communication on behalf of the Board. The notice confirms that the AGM will not have a physical venue for shareholder attendance, aligning with ongoing regulatory permissions for remote meetings.

Key Meeting Details

Shareholders holding shares in physical form are requested to register their email addresses and bank account details with the Registrar and Share Transfer Agent, M/s Bigshare Services Private Limited, or via the company’s website. Those holding shares in dematerialized form must update their details with their respective Depository Participants. These steps are critical for receiving the AGM notice electronically and for the payment of dividends, which are now mandated to be paid only in electronic mode to KYC-compliant folios.

What the Numbers Show

While this filing is procedural, it highlights Marksans Pharma’s adherence to digital governance standards. The exclusive use of VC/OAVM reflects the broader shift in Indian corporate governance towards remote accessibility. Shareholders must act promptly to update their KYC and bank mandates to avoid missing dividend entitlements or voting rights. The absence of physical presence requirements reduces logistical overhead but places the onus on investors to maintain accurate digital records with their depositories or RTAs.